Clinical Trials Directory

Trials / Terminated

TerminatedNCT02221505

Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia

A Phase I, Multicenter, Open-label Dose Escalation and Expansion Study of LOP628, Administered Intravenously in Adult Patients With cKit-positive Tumors and Acute Myeloid Leukemia

Status
Terminated
Phase
Phase 1
Study type
Interventional
Enrollment
3 (actual)
Sponsor
Novartis Pharmaceuticals · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

LOP628 is an antibody-drug conjugate (ADC) consisting of an anti-cKit humanized IgG1/κ antibody conjugated to a maytansine payload via a non-cleavable linker. LOP628 provides an opportunity to target cKit overexpressing tumors.

Conditions

Interventions

TypeNameDescription
DRUGLOP628

Timeline

Start date
2014-12-01
Primary completion
2015-03-01
Completion
2015-03-01
First posted
2014-08-20
Last updated
2016-04-05

Locations

4 sites across 4 countries: Australia, Belgium, Netherlands, Spain

Source: ClinicalTrials.gov record NCT02221505. Inclusion in this directory is not an endorsement.